Contraceptive patch.  The patch should not be applied to the palm.
Find information on thousands of medical conditions and prescription drugs.

Ortho Evra

A contraceptive patch is a transdermal patch applied to the skin that releases synthetic estrogen and progestin hormones to prevent pregnancy. They are thought to have the same effectiveness as the contraceptive pill. Currently the only publicly available contraceptive patch is marketed under the brand name Ortho Evra. Use of this relatively new contraceptive is increasing rapidly, likely because it combines the high effectiveness of contraceptive pills with a more convenient and easy method of administration. Contraceptive patches are often referred to by the slang term "the patch". more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Method of use

In the United States and Canada, Ortho Evra is available only by prescription and is sold in boxes of three patches. Johnson & Johnson is the largest manufacturer of these patches.

A woman applies her first patch onto her upper outer arm, buttocks, abdomen or thigh on either the first day of her menstrual cycle (day 1) or on the first Sunday following that day, whichever she prefers. The day of application is known from that point as patch change day. Seven days later, when patch change day comes again, the woman removes the patch and applies another in its place. This process is repeated again on the next patch change day. On the following patch change day, the patch is removed and not replaced. The woman waits 7 days without a patch in place, and on the next patch change day she applies a new patch.

Backup contraception

  • If a woman chooses to begin with her patch change day as day 1 of her menstrual cycle, the patch is able to take effect in time to prevent ovulation (see Mechanism of Action below) and no form of backup contraception is needed at all.
    • In the case that a woman wishes to begin using the contraceptive patch following a first trimester abortion or miscarriage, patch application can be done immediately afterwards. This can be considered the same as a day 1 start above, and no backup contraception is required.
  • If a woman chooses to begin with her patch change day as the first Sunday following day 1, it is necessary to use a backup form of contraception such as spermicide or condoms for the first week of patch wear.

Mechanism of action

Contraceptive patches are synthetic hormone contraceptives, similar in action to the contraceptive pill. The contraceptive patch product Ortho Evra contains 0.75 mg ethinyl estradiol and 6.0 mg norelgestromin hormones in a single patch. The gradual release of hormones over the course of each week (approximately 20 µg/day ethinyl estradiol and 150 µg/day norelgestromin) act much like contraceptive pills do. Most commonly ovulation is inhibited entirely, preventing pregnancy. Less often the cervical mucus is thickened, making it more difficult for sperm to cross through the cervix and for fertilization to occur.

Interactions and Contraindications

Contraceptive effectiveness of the patch or any other hormonal contraceptive may be reduced significantly if co-administered alongside various antibiotics, antifungals, anticonvulsants, or other drugs that increase metabolism of contraceptive steroids.

However, despite the interactions with many other antibiotics, a clinical pharamacokinetic drug interaction study showed that oral administration of tetracycline HCl 500 mg for 3 days prior to and 7 days during use of Ortho Evra did not reduce effectiveness of Ortho Evra. This is a significant factor in the common decision to administer tetracycline-derived antibiotics following an abortion (preventatively to fight potential infection) when synthetic hormone contraceptives are to be used afterwards.

Read more at Wikipedia.org


[List your site here Free!]


First contraceptive skin patch - Updates - Ortho Evra - Brief Article - Product Announcement
From FDA Consumer, 1/1/02

The FDA has approved Ortho Evra, the first skin patch for birth control. The prescription patch works by releasing hormones through the skin into the bloodstream to prevent pregnancy.

The square patch, just under two inches wide, consists of three layers. The hormones norelgestromin and ethinyl estradiol are embedded in the adhesive layer and are slowly released when the patch is applied to the skin.

Women using the product should apply it to the lower abdomen, buttocks or upper body, but not to the breasts. The patch is worn continuously for one week and then replaced with a new patch, for a total of three weeks of patch wear. During the fourth week, no patch is used, allowing the woman to have her menstrual period.

Like birth control pills, Ortho Evra is effective for pregnancy prevention when used as directed. The risks of using this product include an increased risk of blood clots, heart attack, and stroke. The product's warning label also notes that cigarette smoking increases the risk of serious cardiovascular side effects.

The FDA approved Ortho Evra following three worldwide clinical trials involving 4,578 women, of whom 3,319 used Ortho Evra. The other women in the trials used birth control pills. The trials demonstrated that that women were able to follow the weekly patch application and changing regimen. About 5 percent of the women had at least one patch that did not stay attached to their skin. About 2 percent withdrew from the trial due to skin irritation from the patch. The product appeared to be less effective in women weighing more than 198 pounds.

Ortho Evra was developed by R. W. Johnson Pharmaceutical Research Institute and is marketed by Ortho-McNeil Pharmaceutical Inc., Raritan, N.J. The product is sold in packages of three patches for the monthly cycle of use.

COPYRIGHT 2002 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Ortho Evra
Home Contact Resources Exchange Links ebay